Your browser is no longer supported. Please, upgrade your browser.
GERN [NASD]
Geron Corporation
Index- P/E- EPS (ttm)-0.35 Insider Own0.16% Shs Outstand318.80M Perf Week2.06%
Market Cap551.82M Forward P/E- EPS next Y-0.30 Insider Trans3.47% Shs Float296.50M Perf Month4.22%
Income-80.90M PEG- EPS next Q-0.07 Inst Own56.40% Short Float18.63% Perf Quarter-5.46%
Sales0.40M P/S1379.55 EPS this Y-135.50% Inst Trans1.06% Short Ratio23.16 Perf Half Y-8.47%
Book/sh0.73 P/B2.37 EPS next Y-11.10% ROA-37.20% Target Price- Perf Year23.57%
Cash/sh0.71 P/C2.42 EPS next 5Y5.00% ROE-43.80% 52W Range0.75 - 2.40 Perf YTD8.81%
Dividend- P/FCF- EPS past 5Y-9.20% ROI-53.60% 52W High-27.92% Beta1.33
Dividend %- Quick Ratio9.60 Sales past 5Y-16.80% Gross Margin- 52W Low130.67% ATR0.08
Employees45 Current Ratio9.60 Sales Q/Q0.00% Oper. Margin- RSI (14)53.48 Volatility6.18% 5.10%
OptionableYes Debt/Eq0.10 EPS Q/Q23.20% Profit Margin- Rel Volume0.87 Prev Close1.67
ShortableYes LT Debt/Eq0.10 EarningsNov 05 AMC Payout- Avg Volume2.38M Price1.73
Recom1.70 SMA205.25% SMA50-0.91% SMA200-0.14% Volume2,081,345 Change3.59%
Aug-03-20Initiated Stifel Buy $3
Nov-19-19Resumed B. Riley FBR Buy $4
Sep-03-19Initiated H.C. Wainwright Buy $4
Aug-15-19Initiated Cantor Fitzgerald Overweight $4
Apr-09-19Upgrade Needham Hold → Buy $3
Jan-31-19Upgrade B. Riley FBR Neutral → Buy $1.50 → $3.25
Oct-02-18Downgrade B. Riley FBR Buy → Neutral $5.75 → $1.50
Jul-05-18Initiated B. Riley FBR, Inc. Buy $5.75
Sep-13-16Reiterated FBR Capital Outperform $6 → $5
Sep-13-16Reiterated FBR & Co. Outperform $6 → $5
Dec-07-15Reiterated Piper Jaffray Overweight $5 → $10
Apr-21-15Initiated Oppenheimer Outperform $5.50
Jun-12-14Upgrade MLV & Co Hold → Buy $2 → $4.25
Mar-12-14Downgrade MLV & Co Buy → Hold $9 → $2
Dec-10-13Upgrade Needham Hold → Buy $10
Dec-10-13Reiterated MLV & Co Buy $8 → $9
Nov-08-13Reiterated MLV & Co Buy $6.50 → $8
Oct-16-13Initiated MLV & Co Buy $6.50
Aug-30-12Initiated Stifel Nicolaus Buy $4
Jun-28-12Initiated Needham Hold
Jan-21-21 04:45PM  
Jan-14-21 04:45PM  
Dec-17-20 01:25PM  
Dec-11-20 08:30AM  
Dec-10-20 08:30AM  
Dec-07-20 06:45PM  
Nov-19-20 04:30PM  
Nov-10-20 04:30PM  
Nov-08-20 07:51AM  
Nov-06-20 10:31AM  
Nov-05-20 07:20PM  
04:25PM  
04:05PM  
Nov-04-20 04:27PM  
Nov-02-20 11:58AM  
Oct-29-20 04:30PM  
Oct-28-20 04:35PM  
12:32PM  
Oct-23-20 09:03AM  
Oct-01-20 04:30PM  
Sep-21-20 08:53AM  
Sep-17-20 04:30PM  
Sep-09-20 09:00AM  
Aug-24-20 10:52AM  
Aug-20-20 04:30PM  
Aug-06-20 04:05PM  
Aug-04-20 04:45PM  
Jul-30-20 04:30PM  
12:33PM  
Jul-27-20 08:28AM  
08:18AM  
Jul-23-20 11:30AM  
Jul-16-20 08:30AM  
Jul-01-20 08:30AM  
Jun-30-20 08:01AM  
Jun-25-20 10:36AM  
08:38AM  
Jun-24-20 12:35PM  
11:30AM  
Jun-22-20 11:28AM  
Jun-19-20 08:50AM  
Jun-12-20 08:30AM  
Jun-11-20 09:04AM  
Jun-10-20 09:30AM  
Jun-09-20 09:44AM  
08:40AM  
Jun-05-20 11:30AM  
07:29AM  
Jun-02-20 09:08AM  
May-29-20 05:00PM  
May-28-20 06:25PM  
04:05PM  
May-27-20 04:30PM  
May-22-20 11:11AM  
08:13AM  
07:15AM  
May-21-20 04:03PM  
04:01PM  
08:30AM  
May-15-20 01:24PM  
May-14-20 02:22PM  
09:05AM  
Apr-30-20 12:33PM  
Apr-16-20 08:30AM  
Apr-09-20 06:08PM  
Apr-08-20 04:30PM  
08:46AM  
Apr-04-20 09:25AM  
Apr-02-20 08:00AM  
Mar-23-20 02:15PM  
12:30PM  
10:45AM  
10:40AM  
10:14AM  
07:00AM  
02:00AM  
Mar-22-20 12:53PM  
11:05AM  
Mar-21-20 03:50PM  
08:03AM  
Mar-20-20 05:14PM  
01:45PM  
01:05PM  
11:30AM  
10:13AM  
09:00AM  
Mar-19-20 08:50PM  
04:55PM  
12:45PM  
12:30PM  
11:00AM  
10:45AM  
01:20AM  
Mar-18-20 08:05PM  
11:25AM  
11:20AM  
10:12AM  
Mar-17-20 08:55PM  
08:17PM  
02:45PM  
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Farrell Elizabeth G.DirectorAug 21Buy1.7317,44130,17319,641Aug 24 08:57 PM